	US 12,440,451 B2
	Compositions and methods using an epigenetic inhibitor
Kai Wucherpfennig, Brookline, MA (US); and Rong En Tay, Boston, MA (US)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Appl. No. 16/477,113
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
PCT Filed Jan. 9, 2018, PCT No. PCT/US2018/013011 § 371(c)(1), (2) Date Jul. 10, 2019, PCT Pub. No. WO2018/132391, PCT Pub. Date Jul. 19, 2018.
Claims priority of provisional application 62/444,703, filed on Jan. 10, 2017.
Prior Publication US 2019/0358265 A1, Nov. 28, 2019
Int. Cl. A61K 9/51 (2006.01); A61K 31/415 (2006.01); A61K 38/17 (2006.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); G01N 33/50 (2006.01)

CPC A61K 9/51 (2013.01) [A61K 31/415 (2013.01); A61K 38/1709 (2013.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); G01N 33/505 (2013.01); A61K 2239/57 (2023.05); G01N 2333/98 (2013.01)]

8 Claims

1. A method for increasing T cell effector function in a T cell population, the method comprising contacting a T cell in the T cell population with a pharmaceutical composition comprising a histone deacetylase 3 (HDAC3) antagonist, wherein the HDAC3 antagonist is RGFP966 and wherein the effect of RGFP966 on T cell effector function is dose-dependent T cell cytotoxicity,

wherein the pharmaceutical composition comprises a delivery vehicle that is a nanoparticle, and

wherein the nanoparticle comprises a moiety that specifically binds to a T cell.